Lee YJ, Oh SH, Park C, Hong M, Lee AR, Yoo HJ, Shin CY, Cheon KA, Bahn GH. Advanced pharmacotherapy evidenced by pathogenesis of autism spectrum disorder.
CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE 2014;
12:19-30. [PMID:
24851117 PMCID:
PMC4022762 DOI:
10.9758/cpn.2014.12.1.19]
[Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/04/2014] [Revised: 03/17/2014] [Accepted: 03/20/2014] [Indexed: 01/08/2023]
Abstract
In clinical practice, pharmacological treatment is mostly focused on behavioral symptoms in everyday life. Nevertheless, persistent effort continues to develop medication for causal treatment. Recent changes in diagnostic criteria from Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision (DSM-IV-TR) to DSM-5 would affect not only diagnosing approaches, but also therapeutic approaches. Because previous pervasive developmental disorders have been integrated into a single entity, the autism spectrum disorder (ASD), we have to prepare for what medications are valuable for the ASD. In this article, we reviewed the following etiological treatment: acetylcholine and glutamate related medicine; amino acid medicine such as secretin, endogenous opioid, and oxytocin; complementary and alternative medicine such as chelating agents, vitamins, and omega-3; promising drugs related to the scope of pharmacogenetics currently under study.
Collapse